Goldman Sachs analyst Patrick Donnelly upgraded Exact Sciences to Buy and raised his price target for the shares to $120 from $85. The current momentum of the Cologuard commercial ramp provides "strong basis" for the company's premium valuation while the combination of positive Cologuard catalysts and new product roll-outs provide upside to current levels, even after the stock's 75% rally since the beginning of 2018, Donnelly tells investors in a research note. He views the Cologuard product cycle as the "most compelling across all of diagnostics." Exact Sciences is a "must-own growth stock" given the "clean runway forward that is largely in its control with potential for discovery value in the pipeline outside of Cologuard," the analyst contends. Donnelly believes the company's story is only strengthening and sees the stock as poised to continue its outperformance moving forward.